

EVOLUTIO CARE INNOVATIONS LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2021

EVOLUTIO CARE INNOVATIONS LIMITED
REGISTERED NUMBER: 08099238

CONSOLIDATED BALANCE SHEET
AS AT 31 MARCH 2021

Note		2021 £	2020 £
Fixed assets			
Intangible assets	4	781,480	1,059,238
Tangible assets	5	471,791	455,044
		<u>1,253,271</u>	<u>1,514,282</u>
Current assets			
Debtors: amounts falling due within one year	8	634,546	381,377
Cash at bank and in hand		397,920	633,140
		<u>1,032,466</u>	<u>1,014,517</u>
Creditors: amounts falling due within one year	9	(1,372,987)	(1,078,627)
Net current liabilities		<u>(340,521)</u>	<u>(64,110)</u>
Total assets less current liabilities		<u>912,750</u>	<u>1,450,172</u>
Creditors: amounts falling due after more than one year	10	(81,517)	(82,608)
Provisions for liabilities			
Deferred taxation	11	(208,939)	(257,342)
		<u>(208,939)</u>	<u>(257,342)</u>
Net assets excluding pension asset		<u>622,294</u>	<u>1,110,222</u>
Net assets		<u><u>622,294</u></u>	<u><u>1,110,222</u></u>
Capital and reserves			
Called up share capital	12	133	133
Share premium account		1,998,966	1,998,966
Profit and loss account		(1,376,805)	(888,877)
Equity attributable to owners of the parent Company		<u>622,294</u>	<u>1,110,222</u>
		<u><u>622,294</u></u>	<u><u>1,110,222</u></u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

EVOLUTIO CARE INNOVATIONS LIMITED
REGISTERED NUMBER: 08099238

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2021

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

P Price-Taylor
Director

Date: 21 December 2021

The notes on pages 5 to 20 form part of these financial statements.

EVOLUTIO CARE INNOVATIONS LIMITED
REGISTERED NUMBER: 08099238

COMPANY BALANCE SHEET
AS AT 31 MARCH 2021

	Note	2021 £	2020 £
Fixed assets			
Intangible assets	4	781,480	1,059,238
Tangible assets	5	469,266	451,346
Investments	6	-	88
		<hr/>	<hr/>
		1,250,746	1,510,672
Current assets			
Debtors: amounts falling due within one year	8	621,501	1,156,552
Cash at bank and in hand		318,360	568,465
		<hr/>	<hr/>
		939,861	1,725,017
Creditors: amounts falling due within one year	9	(1,333,197)	(1,044,726)
		<hr/>	<hr/>
Net current (liabilities)/assets		(393,336)	680,291
		<hr/>	<hr/>
Total assets less current liabilities		857,410	2,190,963
Creditors: amounts falling due after more than one year	10	(81,517)	(82,608)
Provisions for liabilities			
Deferred taxation	11	(208,939)	(257,342)
		<hr/>	<hr/>
		(208,939)	(257,342)
		<hr/>	<hr/>
Net assets excluding pension asset		566,954	1,851,013
		<hr/>	<hr/>
Net assets		566,954	1,851,013
		<hr/>	<hr/>
Capital and reserves			
Called up share capital	12	133	133
Share premium account		1,998,966	1,998,966
Profit and loss account		(1,432,145)	(148,086)
		<hr/>	<hr/>
		566,954	1,851,013
		<hr/>	<hr/>

The directors consider that the Company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

EVOLUTIO CARE INNOVATIONS LIMITED
REGISTERED NUMBER: 08099238

COMPANY BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2021

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

P Price-Taylor
Director

Date: 21 December 2021

The notes on pages 5 to 20 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

1. General information

The Company is a private company limited by share capital and incorporated in England and Wales (registered number 08099238) under the Companies Act. The address of the principal place of business is Newtown House, Newtown Road, Henley on Thames, Oxfordshire, RG9 1HG.

The following principal accounting policies have been applied:

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 Basis of consolidation

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated statement of comprehensive income from the date on which control is obtained. They are deconsolidated from the date control ceases.

2.3 Going concern

The directors have considered the impact of the global Covid-19 pandemic on the ability of the company to continue trading for the foreseeable future. This review has included considering the impact of the pandemic to the date of signing the financial statements and updating financial projections. Based on this review and taken together with existing financing facilities the directors believe that the financial statements have been prepared appropriately on the going concern basis.

2.4 Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.5 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable for services during the year, excluding discounts, rebates, value added tax and other sales taxes.

2.6 Research and development

To 31 March 2016 expenditure on research and development was written off in the year in which it was incurred, since the company was in a period of research with no definable intangible asset that could be taken to market.

From 1 April 2016 development costs are capitalised within intangible assets where they can be identified with a specific product or project anticipated to produce future benefits and are amortised on the straight line basis over the anticipated life of the benefits arising from the completed product or project.

The anticipated life of the capitalised assets is considered to be 5 years and assets are amortised from the point when they start generating income.

Deferred research and development costs are reviewed annually and where future benefits are deemed to have ceased, or to be in doubt, the balance of any related research and development is written off to the profit and loss account.

2.7 Pensions

Defined contribution pension plan

The Group operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Group in independently administered funds.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.8 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company and the Group operate and generate income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.9 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Relationship goodwill of £30,000 and triage algorithms goodwill of £26,000, both acquired in 2015, are being amortised evenly over their estimated useful life of ten years.

Patents and other intellectual property assets are amortised at varying rates between five and ten years.

2.10 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.10 Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Short-term leasehold property improvements	- over the term of the remaining lease
Plant and machinery	- 25% on cost
Motor vehicles	- 33% on cost
Fixtures and fittings	- 20% on cost
Computer equipment	- 33% on cost

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.11 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

2.12 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.13 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.14 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.15 Provisions for liabilities

Provisions are made where an event has taken place that gives the Group a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to profit or loss in the year that the Group becomes aware of the obligation, and are measured at the best estimate at the Balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Balance sheet.

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

2. Accounting policies (continued)

2.16 Financial instruments

The Group only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

2.17 Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

3. Employees

The average monthly number of employees, including the directors, during the year was as follows:

	Group 2021 No.	Group 2020 No.	Company 2021 No.	Company 2020 No.
	56	40	56	40
Staff				

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

4. Intangible assets

Group

	Trademarks, Patents & IP £	Development expenditure £	Goodwill £	Total £
Cost				
At 1 April 2020	43,399	1,767,464	56,000	1,866,863
Additions	-	98,512	-	98,512
At 31 March 2021	43,399	1,865,976	56,000	1,965,375
Amortisation				
At 1 April 2020	28,987	750,638	28,000	807,625
Charge for the year on owned assets	2,838	367,832	5,600	376,270
At 31 March 2021	31,825	1,118,470	33,600	1,183,895
Net book value				
At 31 March 2021	11,574	747,506	22,400	781,480
At 31 March 2020	14,412	1,016,826	28,000	1,059,238

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

4. Intangible assets (continued)

Company

	Trademarks, Patents & IP £	Development expenditure £	Goodwill £	Total £
Cost				
At 1 April 2020	43,399	1,767,464	56,000	1,866,863
Additions	-	98,512	-	98,512
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2021	43,399	1,865,976	56,000	1,965,375
	<hr/>	<hr/>	<hr/>	<hr/>
Amortisation				
At 1 April 2020	28,987	750,638	28,000	807,625
Charge for the year	2,838	367,832	5,600	376,270
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2021	31,825	1,118,470	33,600	1,183,895
	<hr/>	<hr/>	<hr/>	<hr/>
Net book value				
At 31 March 2021	<u>11,574</u>	<u>747,506</u>	<u>22,400</u>	<u>781,480</u>
At 31 March 2020	<u>14,412</u>	<u>1,016,826</u>	<u>28,000</u>	<u>1,059,238</u>

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

5. Tangible fixed assets

Group

	Short-term leasehold property improvement £	Plant and machinery £	Motor vehicles £	Fixtures and fittings £	Computer equipment £
Cost or valuation					
At 1 April 2020	206,239	412,436	26,705	27,432	187,051
Additions	137,243	87,532	-	7,763	29,759
At 31 March 2021	343,482	499,968	26,705	35,195	216,810
Depreciation					
At 1 April 2020	45,199	221,676	2,599	9,999	125,347
Charge for the year on owned assets	79,742	119,453	8,902	5,681	31,771
At 31 March 2021	124,941	341,129	11,501	15,680	157,118
Net book value					
At 31 March 2021	218,541	158,839	15,204	19,515	59,692
At 31 March 2020	161,040	190,760	24,106	17,433	61,705

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

5. Tangible fixed assets (continued)

	Total £
Cost or valuation	
At 1 April 2020	859,863
Additions	262,297
	<hr/>
At 31 March 2021	1,122,160
	<hr/>
Depreciation	
At 1 April 2020	404,820
Charge for the year on owned assets	245,549
	<hr/>
At 31 March 2021	650,369
	<hr/>
Net book value	
At 31 March 2021	471,791
	<hr/>
At 31 March 2020	455,044
	<hr/>

The net book value of land and buildings may be further analysed as follows:

	2021 £	2020 £
Short leasehold	218,541	161,040
	<hr/>	<hr/>
	218,541	161,040
	<hr/>	<hr/>

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

5. Tangible fixed assets (continued)

Company

	Short-term leasehold property improvement	Plant and machinery	Motor vehicles	Fixtures and fittings	Computer equipment
	£	£	£	£	£
Cost or valuation					
At 1 April 2020	206,239	412,436	26,705	24,476	180,395
Additions	137,243	87,532	-	7,763	28,741
At 31 March 2021	<u>343,482</u>	<u>499,968</u>	<u>26,705</u>	<u>32,239</u>	<u>209,136</u>
Depreciation					
At 1 April 2020	45,199	221,676	2,599	9,112	120,319
Charge for the year on owned assets	79,742	119,453	8,902	5,397	29,865
At 31 March 2021	<u>124,941</u>	<u>341,129</u>	<u>11,501</u>	<u>14,509</u>	<u>150,184</u>
Net book value					
At 31 March 2021	<u>218,541</u>	<u>158,839</u>	<u>15,204</u>	<u>17,730</u>	<u>58,952</u>
At 31 March 2020	<u>161,040</u>	<u>190,760</u>	<u>24,106</u>	<u>15,364</u>	<u>60,076</u>

EVOLUTIO CARE INNOVATIONS LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

5. Tangible fixed assets (continued)

	Total £
Cost or valuation	
At 1 April 2020	850,251
Additions	261,279
	<hr/>
At 31 March 2021	1,111,530
	<hr/>
Depreciation	
At 1 April 2020	398,905
Charge for the year on owned assets	243,359
	<hr/>
At 31 March 2021	642,264
	<hr/>
Net book value	
At 31 March 2021	469,266
	<hr/>
At 31 March 2020	451,346
	<hr/>

The net book value of land and buildings may be further analysed as follows:

	2021 £	2020 £
Short leasehold	218,541	161,040
	<hr/>	<hr/>
	218,541	161,040
	<hr/>	<hr/>

EVOLUTIO CARE INNOVATIONS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

6. Fixed asset investments

Company

	Investments in subsidiary companies £
Cost or valuation	
At 1 April 2020	88
	<hr/>
At 31 March 2021	88
Impairment	
Charge for the period	88
	<hr/>
At 31 March 2021	88
	<hr/>
Net book value	
At 31 March 2021	-
	<hr/>
At 31 March 2020	88
	<hr/>

7. Subsidiary undertaking

The following was a subsidiary undertaking of the Company:

Name	Registered office	Class of shares	Holding
Evolutio Software Services Limited	Paramount Court Sandyford Business Park Dublin 18 D18 R9C7	Ordinary	100 %

The aggregate of the share capital and reserves as at 31 March 2021 and the profit or loss for the year ended on that date for the subsidiary undertaking were as follows:

Name	Aggregate of share capital and reserves	Profit/(Loss)
Evolutio Software Services Limited	1,276,739	440,787

EVOLUTIO CARE INNOVATIONS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

8. Debtors

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Trade debtors	592,478	309,838	580,314	301,322
Amounts owed by group undertakings	-	-	-	786,217
Other debtors	42,068	71,539	41,187	69,013
	<u>634,546</u>	<u>381,377</u>	<u>621,501</u>	<u>1,156,552</u>

9. Creditors: amounts falling due within one year

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Debenture loans	652	610	-	-
Trade creditors	327,436	299,906	325,891	296,370
Corporation tax	6,683	11,538	6,683	11,538
Other taxation and social security	70,463	45,518	60,975	38,306
Obligations under finance lease and hire purchase contracts	118,514	87,638	118,514	87,638
Preference dividends payable	595,054	435,054	595,054	435,054
Other creditors	180,003	123,820	159,133	107,533
Accruals and deferred income	74,182	74,543	66,947	68,287
	<u>1,372,987</u>	<u>1,078,627</u>	<u>1,333,197</u>	<u>1,044,726</u>

The following liabilities were secured:

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Hire purchase	118,514	87,638	118,514	87,638
	<u>118,514</u>	<u>87,638</u>	<u>118,514</u>	<u>87,638</u>

Details of security provided:

The hire purchase liability is secured on the assets on finance.

EVOLUTIO CARE INNOVATIONS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

10. Creditors: amounts falling due after more than one year

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Net obligations under finance leases and hire purchase contracts	81,517	82,608	81,517	82,608
	<u>81,517</u>	<u>82,608</u>	<u>81,517</u>	<u>82,608</u>

The following liabilities were secured:

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Hire purchase	81,517	82,608	81,517	82,608
	<u>81,517</u>	<u>82,608</u>	<u>81,517</u>	<u>82,608</u>

Details of security provided:

The hire purchase liability is secured on the assets on finance.

11. Deferred taxation

Group

	2021 £	2020 £
At beginning of year	(257,342)	(196,938)
Charged to profit or loss	48,403	(60,404)
At end of year	<u>(208,939)</u>	<u>(257,342)</u>

EVOLUTIO CARE INNOVATIONS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

11. Deferred taxation (continued)

Company

	2021	2020
	£	£
At beginning of year	(257,342)	(196,938)
Charged to profit or loss	48,403	(60,404)
At end of year	<u>(208,939)</u>	<u>(257,342)</u>

	Group	Group	Company	Company
	2021	2020	2021	2020
	£	£	£	£
Accelerated capital allowances	(208,939)	(257,342)	(208,939)	(257,342)
	<u>(208,939)</u>	<u>(257,342)</u>	<u>(208,939)</u>	<u>(257,342)</u>

12. Share capital

	2021	2020
	£	£
Allotted, called up and fully paid		
333,283 (2020 - 333,283) Preference shares of £0.0001 each	33	33
1,000,000 (2020 - 1,000,000) Ordinary shares of £0.0001 each	100	100
	<u>133</u>	<u>133</u>

13. Pension commitments

The Group operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £40,654 (2020: £29,470).

Contributions totalling £11,255 (2020: £12,504) were payable to the fund at the balance sheet date and are included in creditors.

EVOLUTIO CARE INNOVATIONS LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021**

14. Commitments under operating leases

At 31 March 2021 the Group and the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Not later than 1 year	64,375	92,792	64,375	92,792
Later than 1 year and not later than 5 years	49,600	115,536	49,600	115,536
	<u>113,975</u>	<u>208,328</u>	<u>113,975</u>	<u>208,328</u>

15. Related party transactions

During the year P Price-Taylor, director, charged £107,864 for providing consultancy services to Evolutio Care Innovations Limited (2020: £98,000).

At the balance sheet date P Price-Taylor owed £nil to Evolutio Care Innovations Limited on a directors loan account (2020: £770). The balance is a non-interest bearing loan with no set repayment date.

16. Controlling party

There is no single controlling party.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.